WO2024158861A1 - Procédé et composition d'hygiène nasale - Google Patents

Procédé et composition d'hygiène nasale Download PDF

Info

Publication number
WO2024158861A1
WO2024158861A1 PCT/US2024/012693 US2024012693W WO2024158861A1 WO 2024158861 A1 WO2024158861 A1 WO 2024158861A1 US 2024012693 W US2024012693 W US 2024012693W WO 2024158861 A1 WO2024158861 A1 WO 2024158861A1
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
mixture
weight
nasal
composition
Prior art date
Application number
PCT/US2024/012693
Other languages
English (en)
Inventor
Paul LOBEL
Bruce Artman
Original Assignee
Actual Natural Health & Wellness Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/101,047 external-priority patent/US20230157945A1/en
Application filed by Actual Natural Health & Wellness Products, Inc. filed Critical Actual Natural Health & Wellness Products, Inc.
Publication of WO2024158861A1 publication Critical patent/WO2024158861A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Definitions

  • This invention relates to a system and method for rinsing a human nasal passage.
  • the nose is a vital organ but is often ignored.
  • the nose is responsible for filtering, warming, and humidifying the air one breathes.
  • Increased air pollution overwhelms the natural function of the nose.
  • Air pollution including ozone, nitric oxide, and nitrogen dioxide can cause lung injury if they are not filtered by the nose.
  • the condition of dry nose reduces the natural filtering and humidifying function of the nose. Air pollution can cause irritation of nose.
  • Cannabinoids are the various chemical constituents of hemp or cannabis.
  • the known cannabinoids include, CBD (Cannabidiol), CBG (Cannabigerol), CBC
  • Cannabis is widely known to be consumed via the mouth, either by smoking or eating foods containing cannabis. Use of cannabis via the nasal passages is not known and would be painful due to the sensitive nature of the mucus membranes in the nasal passages.
  • concentrations of cannabinoids as low as 0.001% by weight when included in a nasal spray were found to provide effective nasal hygiene, pain relief, and a reduction in inflammation.
  • Concentrations of cannabinoids as high as 5% by weight provide effective nasal hygiene without negative effects on the homogenization of the nasal spray.
  • a homogenized mixture of water, cannabinoid, an olfactory stimulant, and inorganic salt when applied to a nasal passage as a mist delivering 0.08 mb to 0.18 mb in each nostril is effective as a nasal wash.
  • a solubilizing agent particularly suited for cannabinoids may also be added, such as those disclosed in U.S. Patent Application 17/527,465, fded November
  • cannabinoids in combination with chlorine dioxide are particularly useful in providing effective nasal hygiene, pain relief, and reducing inflammation of the nose and nasal passages.
  • the system of rinsing a human nasal passage using a mixture comprising water, cannabinoid, a source of chlorine dioxide, and olfactory stimulant dispensed using an apparatus into the nasal passage as a mist is particularly effective at cleaning the nasal passages and reducing inflammation of the nose. It has also been found the addition of one or more of the following allows for a more reliable system for rinsing the nasal passage: inorganic salt, fixative compounds, solubilizers.
  • the inventors have discovered that many cannabis sativa plant extracts cannot effectively be used for nasal hygiene.
  • the levels of terpene and other naturally occurring compounds in many cannabis sativa plant extracts that are easily tolerated by users of oral and oral vapor delivery devices create irritation of the membranes in the nasal cavity.
  • the membranes in the nasal cavity range from 10-15 pm thick as compared to the healthy epithelium having a mean thickness of 335.59 ⁇ 150.73 pm. According to its location within the oral cavity, the epithelium showed highest values in the region of the buccal mucosa (659.79 pm) and the thinnest one was observed in the mouth’s floor (100.07 pm).
  • a novel non-irritating hygienic composition for use in the system consisting essentially of a product of compounding under homogenizing conditions water, 0.01% to 3% by weight of at least one olfactory stimulant; 0.001% to 5% by weight of cannabinoid; 0 to 5% by weight of at least one fixative compound less volatile than the olfactory stimulant; 0.1 to 2.5% by weight of at least one inorganic salt selected from the group consisting of alkali metal chloride, alkali metal bicarbonate, and alkali metal chlorate.
  • a novel non-irritating hygienic mixture for use in the system consisting essentially of a product of compounding under homogenizing conditions water, 0.01% to 5% by weight, as chlorine dioxide, or a source of chlorine dioxide; 0.01% to 3% by weight of at least one olfactory stimulant; 0.001% to 5% by weight of cannabinoid; 0 to 5% by weight of at least one fixative compound less volatile than the olfactory stimulant; 0.1 to 2.5% by weight of at least one inorganic salt selected from the group consisting of alkali metal chloride, alkali metal bicarbonate, and alkali metal chlorate.
  • the further addition of at least one unsaturated fatty acid to the mixture in the amount of 0.01% to 1% by weight by weight increases the moisturizing effect of the composition on the nasal passages and reduces oxidizing air pollution.
  • the addition of at least one unsaturated fatty acid also enhances the ability of the nasal passages to filter particulate matter from polluted air.
  • the unsaturated fatty acid is a monounsaturated fatty acid, such as omega-7 fatty acids and omega-9 fatty acids, or a polyunsaturated fatty acid, such as omega-3 fatty acids.
  • the compound may also contain combinations of monounsaturated fatty acid and polyunsaturated fatty acid.
  • the composition comprises plant-based sources of unsaturated fatty acid.
  • composition is open only to such additional ingredients as do not adversely affect its beneficial properties.
  • additional ingredients and concentrations of ingredients, as render the composition irritating to the mucous membrane inside the nose, are excluded.
  • a fixative compound less volatile than the olfactory stimulant is given.
  • the term “product compounded under homogenizing conditions” defines a product that has been subjected to heat treatment and mechanical action sufficient to minimize a tendency to separate into two liquid phases. Heat treatment at moderately elevated temperatures in the range of 30 to 55°C. for a period of 1 to 2000 seconds is generally sufficient. Equipment for applying mechanical action is well known in the art and commercially available. The inventors have discovered the disclosed product remains homologous for at least 90 days and inclusion of an emulsifier with the cannabinoid provides a mixture that remains homogonous for at least 180 days.
  • Practicing nasal hygiene by the use of the method of applying to a person’s nostril a mist of nasal wash composition comprising the product of compounding under homogenizing conditions water, an amount of a source of chlorine dioxide, 0. 1 to 1% by weight cannabinoid;
  • use of the present composition reduces nasal irritation.
  • Daily flushing or washing out the nose according to the invention has been found through testing to reduce inflammation, reduce pain, and moisturize the nasal passages more effectively than previous washes.
  • the system and method of the inventions uses a mixture or composition that includes at least one cannabinoid.
  • the cannabinoids CBG (Cannabigerol), CBC (Cannabichromene), CBDA (Cannabidiolic acid synthase), CBDV (Cannbidivarin), Delta-8- tetrahydrocannabinol an isomer of delta-9-tetrahydrocannabinol (THC), CBN (Cannabinol), Delta-9-Tetrahydrocannabinol (THC), THCA (Tetrahydrocannabinolic acid), THCV (Tetrahydrocannabivarin), and CBD (Cannabidiol) are preferred.
  • At least two cannabinoids are combined. Some embodiments also include cannabinoids (or combinations of cannabinoids) that are water soluble or water dispersible. Preferred embodiments include a combination of at least five cannabinoids that are water soluble or water dispersible to provide a full or broad spectrum of various cannabinoids. It is further preferred that the cannabinoids used in the composition are converted to isolate. The use of cannabinoid isolate removes most of the terpenes found in cannabis. It is preferable that the mixture or composition explicitly excludes terpenes found in traditional extractions of hemp because these are particularly irritating to the nose and nasal passages.
  • Some of the preferred embodiments of the invention include a source of chlorine dioxide.
  • the inclusion of chlorine dioxide in nasal spray is described in U.S. Pat. No. 7,029,705 and is hereby incorporated by reference.
  • the preferred embodiment includes sufficient chlorine dioxide source to provide 0.01 to 5% by weight chlorine dioxide upon conversion thereto. More preferably, 0.1 to 2% chlorine dioxide.
  • water-soluble isolate versions of cannabinoids are used as a component of the spray. Testing has shown that use of water-soluble isolate prevents irritation, including watery eyes, ringing in the ears and lengthy discomfort in the nose.
  • the cannabinoids incorporated into the nasal spray are 100% water dispersible and combined with a natural emulsifier guaranteeing the cannabinoids maintain solubility providing consistent dosage in every dose.
  • water-soluble cannabis formulations include those disclosed in U.S. Pat. Nos. 9,907,823, 10,046,018, and 10,328,111 and U.S. Pat. Application 16/977,200, the entireties of which are incorporated herein by reference.
  • an improved method of practicing nasal hygiene comprising the steps of applying to a person's nostril a non-irritating hygienic composition consisting essentially of a product of compounding under homogenizing conditions water, 0.01% to 5% by weight, as chlorine dioxide, of a source of chlorine dioxide; 0.01% to 3% by weight of at least one olfactory stimulant; 0.001% to 5% by weight of cannabinoids; 0 to 5% by weight of at least one fixative compound less volatile than the olfactory stimulant 0.1 to 2.5% by weight of at least one inorganic salt selected from the group consisting of alkali metal chloride, alkali metal bicarbonate, and alkali metal chlorate; and 0.0002 to 0.006% (as aluminum) by weight of at least one water soluble aluminum compound, provided that the total concentration of inorganic salt is in the range from 0.6% by weight to 2.5% by weight, holding the composition within the nostril for a hy
  • the olfactory stimulant ingredient can be a cycloaliphatic alcohol, a cycloaliphatic ketone, an aromaticnon-phenolic hydroxyl compound, an aromatic ether, a phenol having nine or more carbon atoms, or a mixture of such compounds.
  • the olfactory stimulant ingredient can also be a mixture of volatile oils or ethereal oils derived from plant materials.
  • Illustrative cycloaliphatic alcohols include cyclododecanol, 3,3,5- trimethylcyclohexanol, and 4-t-butylcyclohexanol.
  • Illustrative cycloaliphatic ketones include exaltone, fenchone, isophorone, muscone, and 3,3,5-trimethylcyclohexanone.
  • Illustrative aromatic non-phenolic hydroxyl compounds include 1 -phenyl ethanol, 2-phenylethanol, and 1- phenoxy -2 -propanol.
  • Illustrative aromatic ethers include diphenyl ether and 2- methoxynaphthalene.
  • Illustrative phenols include p-t-octylphenol and 2,6-di-t-butyl-4- methylphenol.
  • Particularly preferred olfactory stimulant ingredients include thymol, eucalyptol, borneol, menthol, camphor, oil of eucalyptus, pine oil, and gum benzoin.
  • Fixative compound when present is less volatile than the olfactory stimulant ingredient and can be, for example, an essential oil.
  • Particularly preferred fixative compounds include oil of sweet birch, oil of spearmint, oil of pine, and cinnamon.
  • oils extracted from plant materials include olfactory stimulants compounds as well as less volatile fixative type compounds and can serve as sources of both.
  • Particularly preferred dual function oils of this type include basil, bergamot, lemon, citrus, jasmine, lemongrass, rosemary, sage, thyme, and vanilla.
  • the quantity of olfactory stimulant material in the composition of the invention is in the range from 0.01% to 3% by weight, preferably in the range from 0.05% to 1% by weight.
  • the preferred embodiment includes at least three olfactory stimulants.
  • the quantity of fixative material when present is in the range from 0.01% to 5% by weight, preferably in the range from 0.05% to 1% by weight.
  • the unsaturated fatty acid ingredient can be a monounsaturated fatty acid, such as omega-7 fatty acids and omega-9 fatty acids, or a polyunsaturated fatty acid, such as omega-3 fatty acids.
  • the unsaturated fatty acid ingredient can also be a mixture of monounsaturated and polyunsaturated fatty acids.
  • the unsaturated fatty acids are derived from plant materials.
  • Illustrative unsaturated fatty acids include palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, erucic acid, elaidic acid, gondoic acid, mead acid, nervonic acid, ximenic acid, hexadecatrienoic acid, a-linolenic acid, stearidonic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, heneicosapentaenoic acid, docosapentaenoic acid, clupanodonic acid, docosahexaenoic acid, tetracosapentaenoic acid, tetracosahexaenoic acid, linoleic acid, gamma-linolenic acid, calendic acid, eicosadienoic acid, dihomo-gamm
  • Particularly preferred unsaturated fatty acid ingredients include walnut oil, clary sage seed oil, algal oil, flaxseed oil, pomegranate seed oil, borage seed oil, and sea buckthorn oil. These oils may also operate as a fixative compound.
  • the quantity of unsaturated fatty acid in the composition of the invention is in the range from 0.01% to 1% by weight, preferably in the range from 0.05% to 1% by weight.
  • Preferred cannabinoids include CBD (Cannabidiol), CBG (Cannabigerol), CBC (Cannabichromene), CBDA (Cannabidiolic acid synthase) CBDV (Cannbidivarin) CBN (Cannabinol), Delta-9-Tetrahydrocannabinol (A9 THC), Delta-8-Tetrahydrocannabinol (A8 THC), THCA (Tetrahydrocannabinolic acid), THCV (Tetrahydrocannabi varin).
  • the total concentration of cannabinoids is 0.001% to 5% by weight. It is best incorporated into the composition as an oil or aqueous extract of hemp.
  • the concentration of psychoactive Delta-9-Tetrahydrocannabinol is 3% by weight or less. Most preferably the concentration of Delta-9-Tetrahydrocannabinol is between 0.001% and 0.3% by weight.
  • CBD Cannabidiol
  • A8 THC Delta-8-Tetrahydrocannabinol
  • 1% to 4 % of CBD combined with 0.04% to 0.08% A8 THC was found to be particularly effective at washing nasal passages and reducing inflammation.
  • Concentrations of CBD at 0.3% by weight were found to provide effective pain relief during testing.
  • the inorganic salt ingredients of the composition i.e. alkali metal chloride, alkali metal bicarbonate, and alkali metal chlorate, can be lithium salts, potassium salts, sodium salts, and mixtures thereof.
  • salts of different metals for example a sodium salt and a potassium salt
  • ionization in the solution can associate a metal ion with the anion of a different salt from that supplied with the metal.
  • a solution in which potassium bicarbonate and sodium chloride are dissolved contains potassium chloride as well as potassium bicarbonate, and sodium bicarbonate as well as sodium chloride.
  • the inorganic salt ingredient of the composition provides a multiplicity of functions, including adjusting the osmotic strength and the pH of the composition, and limiting the amount of water passing into the mucous membrane while enhancing the cleansing effect. It is therefore preferred to use a combination of two or more inorganic salts according to the invention.
  • the quantity of each inorganic salt in the composition of the invention is in the range from 0.1% to 2.5% by weight, preferably from 0.3% to 2% by weight, provided that the combined quantity of inorganic salts in the composition of the invention is in the range from 0.6% to 2.5% by weight.
  • the inorganic salt sodium chloride is avoided and other inorganic salts, including magnesium chloride, calcium carbonate, and potassium phosphate are used. It is preferable to keep the concentration of sodium chloride below 0.2% by weight.
  • Optional adjuvants that can be included in low concentrations, typically less than 0.5%, in the composition of the invention to impart desired characteristics include colorants illustrated by sodium copper chlorophyllin, surface active materials illustrated by Polysorbate 80 (an ethoxylated sorbitan ester), and chelating agents illustrated by sodium citrate.
  • the practice of nasal hygiene according to the invention requires only moderate and convenient quantities of the composition. It is sufficient for the user to place a convenient quantity of the composition, which can range from about 0.3 to 3 milliliters, into each nostril and retain it for a holding period which can range from a fraction of a minute to about ten minutes or as long as comfortable, and then remove it as by blowing the nose. Any suitable applicator can be used to place the composition inside the user’s nose. The preferred method of application is to insert the atomizer tip into the nasal entry point a quarter of an inch but no more than half an inch. [0047] The preferred embodiments use a bottle of 50mL or less to hold the composition or mixture for application.
  • the bottle is topped by a manual atomizer pump applicator.
  • the applicator delivers the composition or mixture as a fine mist.
  • the manual atomizer pump dispenses 0.08 m to 0.18 mb of total volume per pump.
  • the preferred method dispenses one to two pumps per nostril.
  • hemp oil with one or more cannabinoids is nano-encapsulated, or encapsulated within nanoparticles.
  • the nano-encapsulated cannabinoid(s) are within the size range of 10 nm to 500 nm. In other embodiments, the nano-encapsulated cannabinoid(s) are within the size range of 5 nm to 700 nm. In further embodiments, nano-encapsulated cannabinoid(s) are within the size range of 1 nm to 999 nm.
  • the hemp oil with one or more cannabinoids is combined with one or more other oils, such as but not limited to one or more of the olfactory stimulants, dual function oils, and/or unsaturated fatty acids discussed herein, and then encapsulated within nanoparticles.
  • the composition is further mixed with water or another solvent before or after nano-encapsulation.
  • the composition with encapsulation in nanoparticles further includes any other component(s) discussed herein.
  • nano-encapsulation of cannabinoids in the present invention allows for cannabinoids to be absorbed into a person’s body more quickly than standard hemp or cannabinoid oil.
  • the use of the term “about” means a range of values including and within 15% above and below the named value, except for nominal temperature.
  • the phrase “about 3 mM” means within 15% of 3 mM, or 2.55 - 3.45, inclusive.
  • the phrase “about 3 millimeters (mm)” means 2.55 mm - 3.45 mm, inclusive.
  • the term “about” means a range of values including and within 15% above and below the named value.
  • “about 5°C” when used to denote a change such as in “a thermal resolution of better than 5°C across 3 mm,” means within 15% of 5°C, or 4.25°C - 5.75°C.
  • nominal temperature such as “about -50°C to about +50°C”
  • the term “about” means ⁇ 5°C.
  • the phrase “about 37°C” means 32°C - 42°C.
  • substantially means to be more-or-less conforming to the particular dimension, range, shape, concept, or other aspect modified by the term, such that a feature or component need not conform exactly.
  • a “substantially cylindrical” object means that the object resembles a cylinder but may have one or more deviations from a true cylinder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition et un procédé d'hygiène nasale pour laver et hydrater le passage nasal. La composition de lavage nasal comprend un composé d'eau homogénéisé liquide, du dioxyde de chlore (ou une source de celui-ci), des stimulants olfactifs, des acides gras insaturés et des agents de fixation. Le composant d'acide gras insaturé comprend de 0,01% à 1% en poids du composé.
PCT/US2024/012693 2023-01-24 2024-01-24 Procédé et composition d'hygiène nasale WO2024158861A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/101,047 2023-01-24
US18/101,047 US20230157945A1 (en) 2018-05-03 2023-01-24 Nasal Hygiene Method and Formulation

Publications (1)

Publication Number Publication Date
WO2024158861A1 true WO2024158861A1 (fr) 2024-08-02

Family

ID=91971130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/012693 WO2024158861A1 (fr) 2023-01-24 2024-01-24 Procédé et composition d'hygiène nasale

Country Status (1)

Country Link
WO (1) WO2024158861A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029705B2 (en) * 2002-07-30 2006-04-18 Fuhr Allan H Nasal hygiene method and composition
WO2010127033A1 (fr) * 2009-04-28 2010-11-04 Alltranz Inc. Préparations de cannabidiol et promédicaments de cannabidiol, et méthodes d'utilisation associées
US20180000727A1 (en) * 2015-01-21 2018-01-04 Michael Willinsky Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaer
US20190192794A1 (en) * 2017-12-26 2019-06-27 Sharon K. Christie Olfactory Delivery Device, System and Method for the Delivery of Pharmaceutical Agents
US20200121590A1 (en) * 2015-07-10 2020-04-23 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029705B2 (en) * 2002-07-30 2006-04-18 Fuhr Allan H Nasal hygiene method and composition
WO2010127033A1 (fr) * 2009-04-28 2010-11-04 Alltranz Inc. Préparations de cannabidiol et promédicaments de cannabidiol, et méthodes d'utilisation associées
US20180000727A1 (en) * 2015-01-21 2018-01-04 Michael Willinsky Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaer
US20200121590A1 (en) * 2015-07-10 2020-04-23 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
US20190192794A1 (en) * 2017-12-26 2019-06-27 Sharon K. Christie Olfactory Delivery Device, System and Method for the Delivery of Pharmaceutical Agents

Similar Documents

Publication Publication Date Title
EP2613793B1 (fr) Spray nasal
JP4111916B2 (ja) 口内乾燥症の軽減および関連疾病の治療のための組成物
JP2005504109A5 (fr)
WO2013065051A1 (fr) Formulation et dispositif utilisés dans le traitement de la céruminose
JPH06503567A (ja) 局所感染の治療
NL1029684C2 (nl) Marrubiïne en samenstelling voor de vermindering van snurken, verpakking en werkwijze.
US7029705B2 (en) Nasal hygiene method and composition
WO2024158861A1 (fr) Procédé et composition d'hygiène nasale
JP2002521407A (ja) 鼻孔および副鼻腔清涼化用組成物
US10945982B1 (en) Nasal hygiene method and composition
US20230157945A1 (en) Nasal Hygiene Method and Formulation
JP3262091B2 (ja) 洗眼剤組成物、洗眼剤組成物のべたつき感を解消する方法及び洗眼用セット
JP4827379B2 (ja) クロロブタノール含有人工涙液
JP4733333B2 (ja) 点鼻剤又は洗鼻剤
KR20060041347A (ko) 에센셜 오일을 함유한 치약 조성물
US11110056B1 (en) Nasal hygiene method and composition
JP2005187404A (ja) 粘膜外用噴霧組成物、点鼻剤及び口腔・咽喉疾患用剤
FR3099051A1 (fr) Composition pour pulvérisation nasale ou buccale contenant du soufre
JP5191156B2 (ja) 外用組成物
DK181405B1 (en) Gel for Intranasal Application, its Provision and Use
CN108853487A (zh) 一种治疗口腔溃疡的口腔护理液及其制备方法
JP4084329B2 (ja) 液状組成物およびその製造方法
WO2024042992A1 (fr) Composition de lavage de cavité nasale
JP2004196676A (ja) 点鼻剤
JP2022014902A (ja) 液体組成物の発泡を抑制する方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24747714

Country of ref document: EP

Kind code of ref document: A1